• Molecular NamePiroxicam
  • SynonymAK1015; piroxicam
  • Weight331.352
  • Drugbank_IDDB00554
  • ACS_NO36322-90-4
  • Show 3D model
  • LogP (experiment)3.06
  • LogP (predicted, AB/LogP v2.0)2.22
  • pka6.3
  • LogD (pH=7, predicted)0.71
  • Solubility (experiment)0.023 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.66
  • LogSw (predicted, AB/LogsW2.0)0.1
  • Sw (mg/ml) (predicted, ACD/Labs)0.4
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds2
  • TPSA107.98
  • StatusFDA approved
  • AdministrationPO
  • PharmacologyA non-steroidal anti-inflammatory drug used to relieve the symptoms of rheumatoid and osteoarthritis, primary dysmenorrhoea, postoperative pain; and act as an analgesic, especially where there is an inflammatory component.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2-4.45
  • Bioavailability99.0
  • Protein binding99.0
  • Volume of distribution (VD)0.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPiroxicam is oxidated to hydroxy derivative with further conjugation in the kidneys. It also undergoes the cyclization and deamidation. All products of peroxicam metabolism are pharmacologically inactive.
  • Half life30~60 h
  • Excretion4 to 10% renal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include drowsiness, nausea, stomach pain, and/or vomiting.
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=360 (peroral)